

## Appendix 2B

### Undertaking regarding material events impacting Valuation

**Date:** October 09, 2025

**To,**  
**General Manager**  
**Department of Corporate Services,**  
**BSE Limited**  
P.J. Towers, Dalal Street,  
Mumbai - 400 001  
**BSE Security Code: 544292**

**To,**  
**Manager - Listing Compliance**  
**National Stock Exchange of India Limited**  
‘Exchange Plaza’. C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
**NSE Symbol: ONESOURCE**

Dear Madam/ Sir,

**Re: Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) under Sections 230 to 232 read with Section 234, Section 52, Section 66 and other applicable provisions of the Indian Companies Act, 2013 and the provisions of Section 210 read with Section 212 and other applicable provisions of the Singapore Companies Act, 1967, amongst Steriscience Specialties Private Limited (“SSPL” or “Transferor Company 1”) and Brooks Steriscience Limited (“BSL” or “Transferee Company 1” or “Transferor Company 2”) and Steriscience Pte. Limited (“Steriscience SG” or “Transferor Company 3”) and Strides Pharma Services Private Limited (“SPSPL” or “Transferor Company 4”) and OneSource Specialty Pharma Limited (“OneSource” or “Transferee Company 2”) and their respective shareholders ( the “Scheme” or “Draft Scheme”)**

With reference to the above, we certify/confirm that:-

- i. No material event impacting the valuation has occurred during the intervening period of filing the scheme documents with the Stock Exchange(s) and the period under consideration for valuation.

For and on behalf of **OneSource Specialty Pharma Limited**

---

**Trisha A**  
**Company Secretary**  
**ICSI Membership No.: A47635**  
**Date:** October 09, 2025